Nalaganje...

The Differential and Combined Action of Insulin Glargine and Lixisenatide on the Fasting and Postprandial Components of Glucose Control

BACKGROUND: iGlarLixi is an injectable combination of long acting insulin glargine (iGlar) and glucagon-like peptide 1 receptor agonist lixisenatide in a fixed ratio, which was proven safe and effective for the treatment of type 2 diabetes. Lixisenatide and iGlar act differently on fasting and postp...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Diabetes Sci Technol
Main Authors: Gautier, Thibault, Umpierrez, Guillermo, Renard, Eric, Kovatchev, Boris
Format: Artigo
Jezik:Inglês
Izdano: SAGE Publications 2019
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8256059/
https://ncbi.nlm.nih.gov/pubmed/31810389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1932296819891170
Oznake: Označite
Brez oznak, prvi označite!